Keywords
Last Name
Institution

Jay Schneider

TitleProfessor
InstitutionThomas Jefferson University
DepartmentAnatomy
Address1020 Locust St.
Philadelphia PA 19107
Phone215-503-0370
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R03DE007282     (SCHNEIDER, JAY S)Sep 1, 1985 - Nov 30, 1987
    NIH/NIDCR
    BASAL GANGLIA-TRIGEMINAL INTERACTIONS
    Role: Principal Investigator

    R03MH041645     (SCHNEIDER, JAY S)Aug 1, 1986 - Apr 30, 1988
    NIH/NIMH
    NEUROPSYCHOLOGICAL STUDIES OF MPTP-INDUCED DOPAMINE
    Role: Principal Investigator

    R01NS023980     (SCHNEIDER, JAY S)Feb 1, 1988 - Jun 30, 2001
    NIH/NINDS
    NEUROBEHAVIORAL PLASTICITY AFTER DOPAMINE SYSTEM DAMAGE
    Role: Principal Investigator

    R03DE008991     (SCHNEIDER, JAY S)Aug 1, 1988 - Jul 31, 1990
    NIH/NIDCR
    PHARMACOLOGICAL STUDIES OF TRIGEMINAL-BASAL GANGLIA
    Role: Principal Investigator

    R01MH046531     (SCHNEIDER, JAY S)Sep 30, 1991 - Apr 30, 2001
    NIH/NIMH
    NEUROPSYCHOLOGY OF CATECHOLAMINE DEFICIENCIES
    Role: Principal Investigator

    R01AG010280     (SCHNEIDER, JAY S)Sep 30, 1992 - Jul 31, 1996
    NIH/NIA
    DEGENERATION, REPAIR AND AGING IN THE CNS
    Role: Principal Investigator

    R01NS038681     (SCHNEIDER, JAY S)Jun 1, 1999 - May 31, 2010
    NIH/NINDS
    GM1 Ganglioside Effects on Parkinson's Disease
    Role: Principal Investigator

    R01DA013452     (SCHNEIDER, JAY S)Jul 1, 2000 - Feb 28, 2010
    NIH/NIDA
    Nicotine and Cognition in Parkinsonism
    Role: Principal Investigator

    U10NS044481     (SCHNEIDER, JAY S)Sep 30, 2002 - Nov 30, 2015
    NIH/NINDS
    NIH Exploratory Trials in Parkinson's Disease (NET-PD): Clinical Site
    Role: Principal Investigator

    R01ES015295     (SCHNEIDER, JAY S)Dec 1, 2006 - Apr 30, 2018
    NIH/NIEHS
    Environment and Gene Effects on Brain and Behavior
    Role: Principal Investigator

    R01NS055916     (SCHNEIDER, JAY S)Jan 15, 2008 - Dec 31, 2013
    NIH/NINDS
    Attention and Executive Functioning in Aging and Parkisonism
    Role: Principal Investigator

    R01ES021534     (CORY-SLECHTA, DEBORAH A)Dec 1, 2012 - Oct 31, 2017
    NIH/NIEHS
    CNS Glucocorticoid Epigenetic Changes of Pb Stress Effects
    Role: Co-Principal Investigator

    R21ES024884     (SCHNEIDER, JAY S)Jul 1, 2015 - Jun 30, 2017
    NIH/NIEHS
    Retinal Imaging with Optical Coherence Tomography as a Biomarker for Manganese Neurotoxicity
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Wills AA, Elm JJ, Ye R, Chou KL, Parashos SA, Hauser RA, Bodis-Wollner I, Hinson VK, Christine CW, Schneider JS. Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord. 2016 Oct 8. PMID: 27743701.
      View in: PubMed
    2. Schneider JS, Anderson DW, Kidd SK, Sobolewski M, Cory-Slechta DA. Sex-dependent effects of lead and prenatal stress on post-translational histone modifications in frontal cortex and hippocampus in the early postnatal brain. Neurotoxicology. 2016 May; 54:65-71. PMID: 27018513.
      View in: PubMed
    3. Schneider JS, Seyfried TN, Choi HS, Kidd SK. Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease. PLoS One. 2015; 10(12):e0143351. PMID: 26629687.
      View in: PubMed
    4. Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS. Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol. 2015 Sep-Oct; 38(5):163-9. PMID: 26366971.
      View in: PubMed
    5. Schneider JS, Cambi F, Gollomp SM, Kuwabara H, Brašic JR, Leiby B, Sendek S, Wong DF. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding. J Neurol Sci. 2015 Sep 15; 356(1-2):118-23. PMID: 26099170.
      View in: PubMed
    6. Schneider JS, Sendek S, Yang C. Relationship between Motor Symptoms, Cognition, and Demographic Characteristics in Treated Mild/Moderate Parkinson's Disease. PLoS One. 2015; 10(4):e0123231. PMID: 25905783.
      View in: PubMed
    7. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93. PMID: 25668262.
      View in: PubMed
    8. Umeh CC, Pérez A, Augustine EF, Dhall R, Dewey RB, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O. No Sex Differences in Use of Dopaminergic Medication in Early Parkinson Disease in the US and Canada - Baseline Findings of a Multicenter Trial. PLoS One. 2014; 9(12):e112287. PMID: 25486269.
      View in: PubMed
    9. Schneider JS, Ault ME, Anderson DW. Retinal Pathology detected by optical coherence tomography in an animal model of Parkinson's disease. Mov Disord. 2014 Oct; 29(12):1547-51. PMID: 25070726.
      View in: PubMed
    10. Schneider JS, Talsania K, Mettil W, Anderson DW. Genetic diversity influences the response of the brain to developmental lead exposure. Toxicol Sci. 2014 Sep 1; 141(1):29-43. PMID: 24913800.
      View in: PubMed
    11. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 2014 Apr 15; 29(5):634-50. PMID: 24757112.
      View in: PubMed
    12. Verina T, Schneider JS, Guilarte TR. Manganese exposure induces a-synuclein aggregation in the frontal cortex of non-human primates. Toxicol Lett. 2013 Mar 13; 217(3):177-83. PMID: 23262390.
      View in: PubMed
    13. Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E. Levodopa improves motor deficits but can further disrupt cognition in a macaque parkinson model. Mov Disord. 2013 Apr 15; 28(5):663-7. PMID: 23238827.
      View in: PubMed
    14. Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J Neurol Sci. 2013 Jan 15; 324(1-2):140-8. PMID: 23199590.
      View in: PubMed
    15. Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E. Effects of memantine and galantamine on cognitive performance in aged rhesus macaques. Neurobiol Aging. 2013 Apr; 34(4):1126-32. PMID: 23158762.
      View in: PubMed
    16. Schneider JS, Anderson DW, Talsania K, Mettil W, Vadigepalli R. Effects of developmental lead exposure on the hippocampal transcriptome: influences of sex, developmental period, and lead exposure level. Toxicol Sci. 2012 Sep; 129(1):108-25. PMID: 22641619.
      View in: PubMed
    17. Zeamer A, Clark K, Bouquio C, Decamp E, Schneider JS. Impaired spatial working memory learning and performance in normal aged rhesus monkeys. Behav Brain Res. 2012 Jun 15; 232(1):287-93. PMID: 22546522.
      View in: PubMed
    18. Paule MG, Green L, Myerson J, Alvarado M, Bachevalier J, Schneider JS, Schantz SL. Behavioral toxicology of cognition: extrapolation from experimental animal models to humans: behavioral toxicology symposium overview. Neurotoxicol Teratol. 2012 Mar; 34(2):263-73. PMID: 22311110.
      View in: PubMed
    19. Decamp E, Clark K, Schneider JS. Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates. Eur J Neurosci. 2011 Sep; 34(6):1018-22. PMID: 21883531.
      View in: PubMed
    20. Anderson DW, Schray RC, Duester G, Schneider JS. Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system. Brain Res. 2011 Aug 23; 1408:81-7. PMID: 21784415.
      View in: PubMed
    21. Verina T, Kiihl SF, Schneider JS, Guilarte TR. Manganese exposure induces microglia activation and dystrophy in the substantia nigra of non-human primates. Neurotoxicology. 2011 Mar; 32(2):215-26. PMID: 21112353.
      View in: PubMed
    22. Millan MJ, Buccafusco JJ, Loiseau F, Watson DJ, Decamp E, Fone KC, Thomasson-Perret N, Hill M, Mocaer E, Schneider JS. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol. 2010 Sep; 13(8):1035-51. PMID: 20663270.
      View in: PubMed
    23. Kidd SK, Schneider JS. Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res. 2010 Oct 1; 1354:172-8. PMID: 20654591.
      View in: PubMed
    24. Schneider JS, Elm JJ, Parashos SA, Ravina BM, Galpern WR. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. Parkinsonism Relat Disord. 2010 Sep; 16(8):507-12. PMID: 20598621.
      View in: PubMed
    25. Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Stem Cells Dev. 2010 Jul; 19(7):1017-23. PMID: 19824823.
      View in: PubMed
    26. Schneider JS, Sendek S, Daskalakis C, Cambi F. GM1 ganglioside in Parkinson's disease: Results of a five year open study. J Neurol Sci. 2010 May 15; 292(1-2):45-51. PMID: 20206941.
      View in: PubMed
    27. Yang C, Garrett-Mayer E, Schneider JS, Gollomp SM, Tilley BC. Repeatable battery for assessment of neuropsychological status in early Parkinson's disease. Mov Disord. 2009 Jul 30; 24(10):1453-60. PMID: 19452561.
      View in: PubMed
    28. Burton NC, Schneider JS, Syversen T, Guilarte TR. Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain. Toxicol Sci. 2009 Sep; 111(1):131-9. PMID: 19520674.
      View in: PubMed
    29. Guilarte TR, Burton NC, McGlothan JL, Verina T, Zhou Y, Alexander M, Pham L, Griswold M, Wong DF, Syversen T, Schneider JS. Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem. 2008 Dec; 107(5):1236-47. PMID: 18808452.
      View in: PubMed
    30. Guilarte TR, Burton NC, Verina T, Prabhu VV, Becker KG, Syversen T, Schneider JS. Increased APLP1 expression and neurodegeneration in the frontal cortex of manganese-exposed non-human primates. J Neurochem. 2008 Jun; 105(5):1948-59. PMID: 18284614.
      View in: PubMed
    31. Kulak JM, Fan H, Schneider JS. Beta2* and beta4* nicotinic acetylcholine receptor expression changes with progressive parkinsonism in non-human primates. Neurobiol Dis. 2007 Sep; 27(3):312-9. PMID: 17616467.
      View in: PubMed
    32. Aschner M, Guilarte TR, Schneider JS, Zheng W. Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol. 2007 Jun 1; 221(2):131-47. PMID: 17466353.
      View in: PubMed
    33. Anderson DW, Bradbury KA, Schneider JS. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci. 2006 Dec; 24(11):3174-82. PMID: 17156378.
      View in: PubMed
    34. Schneider JS, Decamp E, Koser AJ, Fritz S, Gonczi H, Syversen T, Guilarte TR. Effects of chronic manganese exposure on cognitive and motor functioning in non-human primates. Brain Res. 2006 Nov 6; 1118(1):222-31. PMID: 16978592.
      View in: PubMed
    35. Guilarte TR, McGlothan JL, Degaonkar M, Chen MK, Barker PB, Syversen T, Schneider JS. Evidence for cortical dysfunction and widespread manganese accumulation in the nonhuman primate brain following chronic manganese exposure: a 1H-MRS and MRI study. Toxicol Sci. 2006 Dec; 94(2):351-8. PMID: 16968886.
      View in: PubMed
    36. Guilarte TR, Chen MK, McGlothan JL, Verina T, Wong DF, Zhou Y, Alexander M, Rohde CA, Syversen T, Decamp E, Koser AJ, Fritz S, Gonczi H, Anderson DW, Schneider JS. Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol. 2006 Dec; 202(2):381-90. PMID: 16925997.
      View in: PubMed
    37. Kulak JM, Carroll FI, Schneider JS. [125I]Iodomethyllycaconitine binds to alpha7 nicotinic acetylcholine receptors in monkey brain. Eur J Neurosci. 2006 May; 23(10):2604-10. PMID: 16817863.
      View in: PubMed
    38. Wade TV, Schneider JS. Striatal preprotachykinin gene expression reflects parkinsonian signs. Neuroreport. 2004 Nov 15; 15(16):2481-4. PMID: 15538179.
      View in: PubMed
    39. Kulak JM, Schneider JS. Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys. Brain Res. 2004 Mar 5; 999(2):193-202. PMID: 14759498.
      View in: PubMed
    40. Lidsky TI, Schneider JS. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain. 2003 Jan; 126(Pt 1):5-19. PMID: 12477693.
      View in: PubMed
    41. Schneider JS, Wade TV. Experimental parkinsonism is associated with increased pallidal GAD gene expression and is reversed by site-directed antisense gene therapy. Mov Disord. 2003 Jan; 18(1):32-40. PMID: 12518298.
      View in: PubMed
    42. Schroeder JA, Schneider JS. GABA(A) and mu-opioid receptor binding in the globus pallidus and endopeduncular nucleus of animals symptomatic for and recovered from experimental Parkinsonism. Brain Res. 2002 Aug 30; 947(2):284-9. PMID: 12176171.
      View in: PubMed
    Schneider's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _